Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach ...
Oct 7, 2014
0
0
University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.
Feb 13, 2014
0
0
An international research team led by University of Pittsburgh Cancer Institute (UPCI) scientists discovered that by preventing cancer cells from entering a state of cellular sleep, cancer drugs are more effective, and there ...
Aug 1, 2013
0
0
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, ...
Apr 9, 2013
0
0
A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium ...
Apr 7, 2013
0
0
The U.S. Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that do not respond to other treatments.
Feb 25, 2013
0
0
(HealthDay)—The Complexity Index in Sarcoma (CINSARC) and Genomic Index prognostic signatures are valid independent methods of assessing synovial sarcoma (SS) prognosis, according to a study published online Jan. 14 in ...
Jan 18, 2013
0
0
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report ...
Nov 21, 2012
0
0
(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according ...
May 23, 2012
0
0
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...
Feb 6, 2012
0
0
